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Abstract
Background: Chordomas are very rare low-grade malignant bone tumors that arise from the embryonic rests of
the notochord. They are characterized by slow growth and long history with frequent local relapses, and
sometimes metastases. While chemotherapy is not efficient, imatinib has shown antitumor activity.
Case presentation: We report on a 76-year-old patient with EGFR-overexpressing advanced chordoma that
progressed on imatinib and subsequently responded to erlotinib during 12 months.
Conclusions: We report the fourth case of advanced chordoma treated with an EGFR inhibitor. We also review the
literature concerning the rationale and potential of EGFR targeting in chordoma.
Background
Chordomas are very rare malignant bone tumors
(approximate incidence rate 0.1/100.000/year), usually
arising in the sacrum, skull base and spine. Median age at
diagnosis is 60 years [1]. Originating in the embryonic
rests of notochord, chordomas show a dual epithelial-
mesenchymal differentiation [2]. Classically, they are low-
grade malignancies characterized by slow growth and a
long history with frequent local relapses. Thus, surgery is
the most common treatment, followed by radiation ther-
apy in case of non-complete resection. After a long local
evolution, chordomas can also give rise to metastases
(20-30%), generally with low growth potential, primarily
in the lungs, but also bones and liver. Chemotherapy has
been frustratingly inactive in chordoma [1], and until
r e c e n t l y ,b e s ts u p p o r t i v ec a r ew a st h eo n l yt h e r a p e u t i c
option in advanced disease. However, the ongoing eluci-
dation of the molecular mechanisms underlying chordo-
mas has led to new therapeutic hopes. Imatinib, which
blocks PDGFRs and KIT activation [3], showed antitu-
mor activity alone [4], then in combination with cisplatin
chemotherapy [5] or mTOR inhibitor [6]. Erlotinib
(Tarceva, Hoffmann-La Roche Ltd., Basel, Switzerland) is
a small molecule tyrosine kinase inhibitor targeting
EGFR (epidermal growth factor receptor) in lung cancer
[7]. Here, we report on a patient with EGFR-overexpres-
sing advanced chordoma that progressed on imatinib and
subsequently responded to erlotinib.
Case presentation
At first diagnosis, in 1999, the patient was a 65-year old
man, Caucasian type, without any specific medical perso-
nal or familial history. His medical story began in January
with chronic and rebel lumbar pain. In April 1999, pelvic
magnetic resonance imaging (MRI) showed a sacral
tumor. A distal sacral and coccygeal surgical resection
was performed. Histological and immunohistochemical
(IHC positivity for CK AE1/AE3, EMA, PS100) analyses
confirmed the diagnosis of chordoma obtained by pre-
operative biopsy. Post-operative radiotherapy was deliv-
ered with a total dose of 60 Grays in 30 fractions.
In April 2006, computed tomography (CT) revealed 3
subcutaneous lesions located behind the left scapula,
below the right scapula, and next to the temporal bone.
Two lesions (near the left scapula and temporal bone)
were surgically removed, and corresponded histologically
to typical relapses of chordoma. Two months later, a new
recurrence was observed with a right supraclavicular
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grays in 10 fractions).
In July 2007, a CT scan revealed disease progression
with appearance of a multilocular tumor under the left
scapula, several infra- and supracentimetric lung nodules
suggesting metastases, and an increase in size of the right
supraclavicular lesion. Once again, the two soft tissue
lesions were surgically removed. Their largest pathologi-
cal diameters were 9 and 5 cm respectively. Histological
analysis confirmed the diagnosis of chordoma. Owing to
the positive margins of the peri-scapular lesion, adjuvant
radiotherapy was delivered (30 grays in 10 fractions),
followed in October 2007 by introduction of imatinib
(400 mg/day orally). Treatment was well tolerated. In
February 2008, a slowly progressive subcutaneous tumor
nodule located under the right scapula was surgically
excised. Histological analysis again confirmed the diagno-
sis of chordoma. Imatinib was continued. Subsequent
clinical examination and imaging monitored the stability
of the disease until February 2009, at which time a CT
scan showed progression at various sites: increase in size
of the lung nodules, right cervical adenopathy, and two
solid lesions located inside the right pectoralis minor
muscle and the right paravertebral back muscle. In spite
of an increased dose of imatinib (600 mg daily), the dis-
ease continued to progress slowly, even though the
patient remained asymptomatic with good performance
status.
Clinical examination and a CT scan in February 2010,
revealed further progression, notably regarding the right
cervical adenopathy (2.2 × 1.5 cm) and the right pectoral
lesion (8.5 × 4.2 cm) (Figure 1). Clinical status deterio-
rated with a performance status equal to ECOG 1-2, and
the appearance of a right anterior thoracic pain. Imatinib
was stopped. Recent reports describing antitumor activity
of EGFR inhibitors in chordoma [8-10] led us to analyze
tumor samples collected from relapses excised in July
2007 and February 2008. Results were similar in both
samples. Immunohistochemistry showed a strong EGFR
staining in ~90% of tumor cells (Figure 2). Tumor DNA
was sequenced and no mutation was discovered in EGFR,
KRAS, BRAF, KIT,a n dPDGFRA. Fluorescent in situ
hybridization (FISH) did not indicate EGFR amplification,
but showed chromosome 7 trisomy in 38% of the tumor
cells. Given these results and the absence of any alterna-
tive therapeutic option, in February 2010, the 76-year-old
patient was started on erlotinib 150 mg daily. After 4
weeks and no side effect, the patient reported a signifi-
cant improvement of asthenia, and the thoracic pain had
completely disappeared. In May 2010, after 3 months of
erlotinib, the patient fared very well, the pectoral lesion
had decreased, and the CT scan revealed a stabilization
of the right cervical adenopathy (2 × 1.5 cm) and a
regression by 53% of the pectoral lesion volume (7.6 ×
2.3 cm). Lung nodules were stable in size and number.
Treatment was continued. In September 2010, a CT scan
(Figure 1) showed further regression of the pectoral
lesion (6.8 × 1.7 cm; regression of the tumor volume by
70% when compared to February 2010). Other lesions,
including the right cervical adenopathy and lung lesions,
were stable. Erlotinib was continued without any signifi-
cant toxicity. In February 2011, after 12 months of erloti-
nib, all target lesions were clinically and radiologically
stable, except the right cervical adenopathy, which pro-
gressed slightly (2.1 × 2.8 cm) and was treated by
radiotherapy.
Discussion
There is currently no standard systemic therapy for
advanced chordoma, which remains incurable. Recent
February 2010
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stop imatinib - start erlotinib
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Response to erlotinib
July 2009
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Figure 1 Cervico-thoracic CT scan showing response to
erlotinib. Three different dates of treatment are shown: July 2009
(on imatinib), February 2010 (progression on imatinib; just before
erlotinib), and September 2010: (response after 7 months of
erlotinib). Two targets lesions are shown (arrows): the right pectoral
lesion (A), and the right cervical adenopathy (B): both progressed
between July 2009 and February 2010 during imatinib treatment,
and responded to erlotinib between February and September 2010:
regression in size of the pectoral lesion (A), and disappearance of
the peripheral contrast enhancement for the adenopathy (B).
A B
Figure 2 Chordoma and EGFR overexpression. A/H&E staining
showing round cells with vacuolated cytoplasm arranged in cord-
like fashion in a myxoid stroma (original magnification × 100). B/
Immunohistochemistry with anti-EGFR antibody showing strong
membranous and cytoplasmic staining of tumor cells (original
magnification × 200; positivity appears in brown).
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led to new therapeutic hopes, particularly with the
demonstration of the antitumor activity of imatinib both
in vitro and in patients [3-6], and the identification of
other potential therapeutic targets such as STAT3 [11],
c-MET [12], and brachyury gene [13]. Our present case
confirms the relative usefulness of imatinib in advanced
chordoma (disease control lasting for nearly two years).
More importantly, it points out the potential interest of
another tyrosine kinase inhibitor, erlotinib, which
resulted in an impressive clinical and radiological
response lasting 12 months.
Three cases of advanced chordoma benefiting from
EGFR inhibitors have been reported to date in the litera-
ture: two were treated with the gefitinib-cetuximab com-
bination [8,9], and one with erlotinib alone [10]. These
cases and ours are summarized in Table 1. Despite long
delays between initial diagnosis and the anti-EGFR treat-
ment (4 years when used in first line [8,10] and 11 years
when used in second (our case) and third lines [9]), clini-
cal benefits and objective tumor regressions were
observed in all cases. Responses were long lasting (4+,
9+, 11+, and 12 months), and while they primarily con-
cerned local relapses, they also implicated lung, node,
and subcutaneous metastases. In two cases, the simulta-
neous use of gefitinib and cetuximab obfuscated the indi-
vidual anitumor contribution of each, whereas the
Singhal case and ours clearly demonstrate the activity of
erlotinib alone without association with the anti-EGFR
antibody. Treatment was well tolerated; it was better for
the case of erlotinib alone (no interruption for toxicity)
than for the cetuximab-gefitinib combination (interrup-
tion lasting 2 and 4 weeks for skin toxicity). Altogether,
these observations suggest that a small molecule tyrosine
kinase inhibitor could very likely be sufficient.
The rationale for treating chordoma with EGFR inhibi-
tors is inspired by recent reports. Weinberger et al
showed strong and correlated IHC expression of EGFR
and c-MET in a series of 12 chordomas [14]. A Polish
study of 21 cases found low to high EGFR expression in
81% of cases and gene amplification in 27% of cases [15].
Activation of the EGFR signaling pathway was reported
in a series of 22 clinical samples [16]. The largest series
analyzed to date (173 clinical samples) confirmed fre-
quent EGFR expression (69%), and high-level EGFR
polysomy in 38% of cases [17]. Phospho-receptor tyrosine
kinase analysis showed EGFR activation in the U-CH1
chordoma cell line and all of the three chordomas ana-
lyzed. Direct sequencing of E G F R ,K R A S ,N R A S ,H R A S ,
and BRAF failed to reveal mutations in 62 cases. The
EGFR inhibitor tyrphostin (AG 1478) inhibited prolifera-
tion of the U-CH1 cell line in vitro and diminished EGFR
phosphorylation in a dose-dependant manner, a finding
supported by inhibition of phosphorylated Erk1/2 and
p-Akt. Altogether, these data clearly implicate aberrant
EGFR signaling in the pathogenesis of chordoma. Bio-
logical analysis of our case confirmed these findings,
with strong EGFR expression, and absence of gene muta-
tion. FISH analysis revealed trisomy of chromosome 7 in
38% of tumor cells, an alteration already reported
in chordomas and frequently associated with c-MET
overexpression [18]. In our case, whether the trisomy of
chromosome 7 is the causal mechanism of EGFR overex-
pression is not certain.
Conclusion
Our case highlights the antitumor activity of EGFR inhi-
bition in advanced chordoma, in agreement with three
other clinical cases previously reported and pre-clinical
data. The targeting of EGFR represents an attractive
Table 1 Four patients with advanced chordoma treated with EGFR targeting therapy
Ref. Sex Location
of
primary
tumor
Date of
initial
diagnosis
Date of
beginning of
EGFR-targeting
therapy
Tumor locations Patient’s
age
Therapy Tumor response Duration
of
response
[8] M Sacral 2001 2005 Local relapse, Inguinal
lymph node, and lung
metastases
52 Cetuximab-
Gefitinib
« Significant regression » of all
lesions after 2 months*
Ongoing
after 9
months
[9] F Cervical 1996 2007 Local relapse 75 Cetuximab-
Gefitinib
Regression by 44% of the
volume after 4 months
Ongoing
after 4
months
[10] M Sacral 2004 2008 Gluteal mass and iliac
lymph nodes
57 Erlotinib Partial response superior to 30%
reduction in tumor bulk after 3
months
Ongoing
after 11
months
Our
case
M Sacral 1999 2010 Lung metastases,
cervical lymph node
and thoracic soft tissue
mass
76 Erlotinib Regression of the thoracic lesion
by 53% of the volume after 3
months, by 70% after 7 months.
12
months
M, male; F, female; *, the size of lesions and degree of objective response are not mentioned
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tive assessment in multicentric clinical trials.
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